Lenacapavir ‘Breakthrough’ HIV Prevention Begins Rollout in Eswatini and Zambia
Five months after U.S. regulators approved lenacapavir, a long-acting HIV prevention injection, the U.S. State Department announced on Nov. 18, 2025 that Eswatini and Zambia have each received 500 doses. The drug, produced by Gilead Sciences and described in scientific coverage as a major innovation, can protect against HIV with just two injections per year. … Read more